IRF3 (S386A, S396A mutant, human, recombinant)

IFR3 (S386A, S396A mutant, human recombinant) contains amino acids corresponding to human IRF3 (Cay-22811) with alanine substituted for serine at positions 386 and 396. Interferon regulatory factor 3 (IRF3) is a member of the IRF family that plays a crucial role in activation of innate immunity and inflammation in response to viral infection, functioning as a molecular switch for antiviral activity. Double-stranded RNA generated during a viral infection leads to IRF3 activation through serine/threonine phosphorylation by TBK1 (Cay-22817) or IKKepsilon (IKBKE) kinases, which induces a conformational change leading to its dimerization, nuclear localization, and association with CREB binding protein (CREBBP)/p300. The complex formed by this association, known as DRAF1, activates transcription of interferon alpha (IFN-alpha) and IFN-beta as well as other IFN-induced genes, which play a critical role in the type 1 IFN-dependent immune response. Various serine residues have been implicated in IRF3 activation, including S386 and S396. TBK1 and IKKepsilon phosphorylation of IRF3 is decreased when serine is replaced with alanine at positions 396, 398, 402, and 405 and with threonine at position 404. Phosphorylation of S386 is essential for IRF3 oligomerization and binding to p300, and phosphorylation of S396, T390, and either S385 or S386 occurs following Sendai viral infection in HEK293 cells.Synonyms: IRF3 Negative Control. Purity: >75% estimated by SDS-PAGE. Source: N-terminal His-tagged human IRF3 (S386A, S396A mutant) expressed in E. coli. Amino Acids: 1-427 (full length). MW: 49.3 kDa. Formulation: (Request formulation change), 50 mM HEPES, pH 8.0, with 150 mM sodium chloride and 10% glycerol.